← Human Trials & Peer-Reviewed Studies
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.
Plain-language guide to PMID 8436744 (1993): double-blind randomized controlled trial of Phosphodiesterase Inhibitors in 1,068 patients.
Key Facts
- PMID
- 8436744
- Journal
- Journal of the American College of Cardiology
- Year
- 1993
- Study type
- Randomized Controlled Trial
- Authors
- Eichhorn EJ et al. (7 authors)
- DOI
- 10.1016/0735-1097(93)90095-i
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Phosphodiesterase Inhibitors, published as a randomized controlled trial.
Who Took Part
According to the abstract, 1,068 patients were involved.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
Serum magnesium levels were measured in 1,068 patients enrolled in a survival study of class III or IV heart failure at the time of double-blind randomization to milrinone, a phosphodiesterase inhibitor, or placebo.
All patients received conventional therapy with digoxin, diuretic drugs and a converting enzyme inhibitor throughout the trial.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Phosphodiesterase Inhibitors and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Phosphodiesterase Inhibitors, so expectations could not easily colour the readings.
Some patients received a placebo instead of Phosphodiesterase Inhibitors, giving a reference point.
The median follow-up period was 6.1 months (range 1 day to 20 months).
What Was Measured
The subject headings attached to it are Heart Failure, Magnesium, Milrinone, Phosphodiesterase Inhibitors, Pyridones, Risk Factors and Survival Analysis.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Phosphodiesterase Inhibitors in 1,068 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1993 (Journal of the American College of Cardiology), a journal based in United States.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.